216 related articles for article (PubMed ID: 29953307)
1. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
Gouveia M; Jesus G; Inês M; Costa J; Borges M
Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
Kang DW; Kim CR; Song JY; Park SK
Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
[TBL] [Abstract][Full Text] [Related]
6. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult.
Ngamprasertchai T; Kositamongkol C; Lawpoolsri S; Rattanaumpawan P; Luvira V; Chongtrakool P; Kaewkungwal J; Chokephaibulkit K; Phisalprapa P
Front Public Health; 2023; 11():1071117. PubMed ID: 37457251
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
[TBL] [Abstract][Full Text] [Related]
11. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
Cho BH; Stoecker C; Link-Gelles R; Moore MR
Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
15. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
Stoecker C; Kim L; Gierke R; Pilishvili T
J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
[TBL] [Abstract][Full Text] [Related]
17. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
[TBL] [Abstract][Full Text] [Related]
18. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
20. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
Castañeda-Orjuela C; De la Hoz-Restrepo F
Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
